Research programme: cocaine abuse therapeutics - Molecular Insight PharmaceuticalsAlternative Names: Cocaine abuse therapies research programme - Molecular Insight Pharmaceuticals; CTDP 31446
Latest Information Update: 05 Jan 2007
At a glance
- Originator Harvard Medical School; Molecular Insight Pharmaceuticals
- Mechanism of Action Biogenic monoamine uptake inhibitors; Dopamine plasma membrane transport protein antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cocaine abuse
Most Recent Events
- 20 Jan 2003 Preclinical trials in Cocaine abuse in USA (unspecified route)